PTEN and prostate carcinoma: Given the high frequency of PTEN inactivation by genomic deletion in prostate cancer using FISH methods (Yoshimoto et al, 2006a), it has become more practical to conduct much larger correlative studies of patient outcome in situations when the PTEN gene is either lost, or retained in tumours.